NCT05902533View on ClinicalTrials.gov

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

August 14, 2026

Study Completion Date

August 14, 2029

Conditions
Anal Cancer
Interventions
RADIATION

Radiation (reduced elective nodal dose (30.6 Gy)

28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.

DRUG

Capecitabine

825 mg/m2 BID (Oral Twice daily on days with RT)

DRUG

Mitomycin c

10 mg/m2 slow IV push Day 1 and 29

Trial Locations (3)

43210

RECRUITING

Ohio State University Medical Center, Columbus

45219

RECRUITING

University of Cincinnati Medical Center, Cincinnati

05405

RECRUITING

University of Vermont, Burlington

All Listed Sponsors
lead

University of Cincinnati

OTHER